Exposomic Contributions to ADRD Pathology and Resilience
National Institutes of Health
Classification and identifiers
- Solicitation number
- RFA-NS-26-031
- Assistance listing (CFDA)
- 93.853
Amount
Amount not published by the funder
Who can apply
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
About this opportunity
The National Institute of Neurological Disorders and Stroke (NINDS) is interested in supporting research projects that investigate how specific neural exposome factors contribute mechanistically to Alzheimer’s disease-related dementias (ADRD) pathology and resilience. For the purposes of this program, exposome factors of interest include, but are not limited to, environmental toxins, sleep and circadian rhythms, stress, and the real-world conditions that modulate them (e.g., light, noise, heat). Applications will be expected to propose research on the synergistic action between multiple exposome factors, and the composite effects of mixtures of exposome factors on neural mechanisms relevant to ADRD. Applicants are encouraged to focus on mechanistic pathways (e.g., microbiome–brain interact...
Related opportunities
- Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)National Institutes of Health
- Centers without Walls for mechanisms of neurodegeneration in Alzheimer’s disease-related dementias (ADRD)National Institutes of Health
- Functional Target Validation for Alzheimer's Disease-Related DementiasNational Institutes of Health
- Research Project Cooperative Agreements in Aging and/or Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) ResearchNational Institutes of Health
- Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer’s and Related Dementias Disease RiskNational Institutes of Health
- Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)National Institutes of Health